Finding the perfect combination
Thursday, August 16, 2012
Two independent research teams have used cell culture methods to show that excessive HGF/SF activity drives resistance to BRAF inhibitors in melanoma. The findings could provide a rationale for combining HGF/SF or MET inhibitors with BRAF inhibitors to overcome treatment resistance in the disease.
To read this article, you must be a SciBX subscriber through BioCentury.
If you have subscribed to SciBX through our partner, Nature Publishing Group, please
http://www.nature.com/scibx. Otherwise, please click below to contact us
or start a free trial.
All contents Copyright © 1993-2013 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
If you are a current subscriber, log in below or in the upper right corner of this
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
SciBX: Science-Business eXchange
BioCentury's weekly translational science journal, published in collaboration with Nature Publishing Group:
Get Free Trial
Selects from hundreds of scientific papers published each week to identify early opportunities for investment, alliances and partnerships
Reports on the most commercially relevant developments
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]